Eluxadoline
Overview and History Indication and applications Mode of action Adverse reactions Warning and Precaution References- Product Name
- Eluxadoline
- CAS No.
- 864821-90-9
- Chemical Name
- Eluxadoline
- Synonyms
- CS-2329;EOS-61916;Eluxadolin;Eluxadoline;JNJ 27018966;API-Diarrhea;The yi lu Lin;Eluxadoline 13CD4;Eluxadoline (Viberzi);Eluxadoline(JNJ 27018966)
- CBNumber
- CB12723517
- Molecular Formula
- C32H35N5O5
- Formula Weight
- 569.65
- MOL File
- 864821-90-9.mol
Eluxadoline Property
- Melting point:
- >180°C (dec.)
- Boiling point:
- 834.2±65.0 °C(Predicted)
- Density
- 1.284±0.06 g/cm3(Predicted)
- storage temp.
- Refrigerator
- solubility
- DMSO (Slightly), Methanol (Slightly)
- form
- Solid
- pka
- 4.01±0.10(Predicted)
- color
- White to Off-White
- CAS DataBase Reference
- 864821-90-9
Safety
- DEA Controlled Substances
- CSCN: 9725
CAS SCH: IV
NARC: N
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H361Suspected of damaging fertility or the unborn child
- Precautionary statements
-
P201Obtain special instructions before use.
P202Do not handle until all safety precautions have been read and understood.
P281Use personal protective equipment as required.
P308+P313IF exposed or concerned: Get medical advice/attention.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- 21522
- Product name
- Eluxadoline
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $63
- Updated
- 2021/12/16
- Product number
- 21522
- Product name
- Eluxadoline
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $293
- Updated
- 2021/12/16
- Product number
- 21522
- Product name
- Eluxadoline
- Purity
- ≥98%
- Packaging
- 25mg
- Price
- $149
- Updated
- 2021/12/16
- Product number
- 21522
- Product name
- Eluxadoline
- Purity
- ≥98%
- Packaging
- 50mg
- Price
- $280
- Updated
- 2021/12/16
- Product number
- E508195
- Product name
- Eluxadoline
- Packaging
- 100mg
- Price
- $640
- Updated
- 2021/12/16
Eluxadoline Chemical Properties,Usage,Production
Overview and History
Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist that can be used for the treatment of diarrhea-predominant irritable bowel syndrome(IBS-D)[1-4]. The mu-, kappa-, and delta-opioid receptors participating in regulating endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. The agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D[1, 4].
Eluxadoline is marketed under the tradename Viberzi(FDA) in US(at may 2015)[1, 2, 4, 5]. It is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces ?uid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. It is also marketed in Europe under the trade name of “Truberzi”[3].
Indication and applications
Eluxadoline is indicated for the treatment of diarrhea-predominant irritable bowel syndrome(IBS-D). It can work directly in the intestines to slow the movement of food during digestion. Eluxadoline also makes the nerves in the intestines less sensitive to stimulation[1, 6].
Mode of action
Eluxadoline takes effect through acting as the antagonist of mu-opioid receptor agonis, kappa opioid receptor agonist and a delta opioid receptor[7,8]. Eluxadoline can be used for diarrhea predominant IBS because it reduces intestinal contractility and normalizes stress-induced acceleration of upper GI transit[9]. Antagonistic activity at the delta receptor minimizes the constipating effect usually seen by mu-opioid receptor agonists alone. Because of it's limited systemic bioavailability, there may be less side effects associated with the use of eluxadoline in comparison with other therapies used to treat diarrhea predominant IBS[10].
Adverse reactions
Common adverse reaction associated with Eluxadoline include constipation, nausea, abdominal pain, upper respiratory tract infection, pancreatitis, sphincter of Oddi spasm, hypersensitivity reactions, vomiting, nasopharyngitis, abdominal distention, bronchitis, dizziness, flatulence, rash, increased ALT, fatigue, viral gastroenteritis and stomach pain[4, 6, 11]. Less common adverse reactions also include gastroesophageal reflux disease, sedation, somnolence, and euphoric mood, respiration disorders such as asthma, bronchospasm, respiration failure and wheezing. Constipation was the most commonly reported adverse reaction in during the treatment by Eluxadoline. Approximately 50% of constipation events occurred within the first 2 weeks of treatment while the majority occurred within the first 3 months of therapy. Similar rates of constipation occurred between the active and placebo arms beyond 3 months of treatment. In severe cases, constipation can even lead to permanent discontinuation of drugs[11].
Warning and Precaution
Eluxadoline is not approved for use by anyone younger than 18 years old[6].
Eluxadoline is contradicted for administration in patients who suffer from a pancreas disorder, severe liver disease, alcoholism, and a blockage in the intestines, a gallbladder disorder, or those whose gallbladder has been removed[12].
People who are allergic to eluxadoline should also be disabled for using. In addition, it is also not allowed for patients who have a history of gallbladder, obstruction digestive problems caused by a muscle valve called the sphincter of Oddi(SFINK-ter of OD-dee), pancreas disorder, severe liver disease, a habit of drinking more than 3 alcoholic beverages per day[12, 13].
To make sure eluxadoline is safe for you; tell your doctor if you have liver disease.
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. It is not known whether eluxadoline passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby[12].
References
- https://www.drugbank.ca/drugs/DB09272
- "Viberzi[eluxadoline] Tablets, for Oral Use, CIV. Full Prescribing Information". Actavis Pharma, Inc. Parsippany, NJ 07054 USA. Retrieved 26 December 2015.
- "Truberzi". European Medicines Agency. 29 September 2016.
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940s000lbl.pdf
- Cash, B. D. "Eluxadoline: a promising therapy that raises many questions. " Translational Gastroenterology & Hepatology 1(2016]: 76.
- https://www.everydayhealth.com/drugs/eluxadoline
- Fujita, Wakako, et al. "Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers." Biochemical Pharmacology 92.3(2014]: 448-456.
- Levycooperman, N, et al. "Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a mixed μand κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist. " Journal of Pharmacology & Experimental Therapeutics 359.3(2016]: 471-481.
- Chen, Hong Yu, J. J. Feng, and T. T. Song. "Eluxadoline, a new drug for treating diarrhea-predominant irritable bowel syndrome." Chinese Journal of New Drugs[2017].
- Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J: Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015 May; 55(5]: 534-42. doi: 10.1002/jcph.442. Epub 2015 Jan 14.
- https://www.rxlist.com/viberzi-drug.htm
- https://www.drugs.com/viberzi.html
- Gawron, A. J., and K. Bielefeldt. "Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome with Eluxadoline." Clinical Gastroenterology & Hepatology the Official Clinical Practice Journal of the American Gastroenterological Association 16.3(2017].
Description
Eluxadoline, originally developed by Janssen and currently marketed by Allergan (formerly Actavis), was approved in May 2015 by the FDA for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Eluxadoline, an orally dosed agent, employs a unique mechanism for IBS-D treatment, as it functions simultaneously as a μ- and κ-opioid receptor agonist and a δ- opioid receptor antagonist, leading to a first-in-class therapy for treatment of IBS-D. Specifically, in animal studies, eluxadoline was found to interact with opioid receptors in the gut, inhibiting neurogenically mediated secretion and reducing intestinal contractility. Additionally, the treatment led to a decrease in stress-induced acceleration of upper GI transit without causing rebound constipation, earning its mark as a first-line therapeutic treatment for IBS-D. In two phase III clinical trials of over 2400 patients with IBS-D, patients taking eluxadoline showed a greater improvement toward the end point (≥30% improvement from their baseline IBS-D score on at least 50% of days treated with eluxadoline) compared to patients treated with placebo.
Uses
Eluxadoline is an orally-active drug used to reduce symptoms of irritable bowel syndrome such as diarrhea and abdominal pain.
Definition
ChEBI: An amino acid amide obtained by the formal condensation of the carboxy group of 4-carbamoyl-2,6-dimethyl-L-phenylalanine with the secondary amino group of 2-methoxy-5-({[(1S)-1-(4-phenylimidazol-2-yl)ethyl]amino}methyl)ben oic acid. It has mixed opioid receptor activity and is used for treatment of irritable bowel syndrome with diarrhoea.
Clinical Use
Mixed mu-opioid receptor agonist, kappa-opioid receptor
agonist, and a-delta opioid receptor antagonist:
Treatment of irritable bowel syndrome with
diarrhoea
Synthesis
The synthesis of eluxadoline begins with preparation of
advanced coupling component 85, which could be completed
via a four-step route from commercially available N-Bocprotected
aminoester 83 . Triflate formation using N-phenyltrifluoromethanesulfinimide in DCM under
basic conditions led to nearly quantitative yield of the desired
triflate, which was subjected to a carbonylation reaction to yield
aryl acid 84 in 94% yield. Employing NH4Cl as a source of
ammonia, amidation of 84 took place in the presence of
PyBOP/HOBt and DIPEA in DMF. Finally, acid 85 was
revealed upon methyl ester saponification with aqueous LiOH
in THF. This sequence provided 85 without purification.
With coupling component 85 in hand and initiated from a HOBt and EDC?¤HCl-mediated coupling of commercial
N-Cbz-L-alanine (86) with commercial 2-amino acetophenone
hydrochloride (87) to provide intermediate 88 in 83%
yield. Addition of NH4OAc and AcOH to a suspension
of 88 in refluxing xylenes furnished the desired imidazole in
excellent yield (95%). Submission of this N-Cbz-imidazole to
hydrogenation conditions (H2, Pd/C, MeOH) enabled
liberation of the free amine to access 89 in quantitative yield
following filtration and concentration. From intermediate 89,
reductive amination with commercially available aryl aldehyde
90 under standard conditions (NaBH4, MeOH) followed by
subsequent coupling of the corresponding crude amine with acid 85 using HOBt/EDC?¤HCl enabled formation of the
carbon framework of eluxadoline (91). Saponification of the
ester within 91 with LiOH in MeOH/THF yielded the
corresponding acid in quantitative yield. Immediate subjection
of this intermediate to acidic conditions (HCl in EtOAc/THF)
led to N-Boc cleavage and isolation of eluxadoline (XII) as the
bis-HCl salt in 71% yield, requiring no further purification.
It should be noted that since this initial report, additional
details for the isolation of eluxadoline in high purity in various
crystal forms and as a zwitterion have been reported,66 although
most reported routes described isolation of this drug in its HCl
salt form.
Drug interactions
Potentially hazardous interactions with other drugs Antibacterials: concentration possibly increased by rifampicin - avoid. Antivirals: concentration possibly increased by atazanavir, lopinavir, ritonavir, saquinavir and tipranavir - avoid. Ciclosporin: concentration of eluxadoline increased - avoid. Lipid-lowering agents: concentration possibly increased by gemfibrozil - avoid.
Metabolism
Eluxadoline is mainly excreted in the faeces, either as unabsorbed active substance or via the biliary system with the kidney playing a minimal role in elimination.
Eluxadoline Preparation Products And Raw materials
Raw materials
Preparation Products
Eluxadoline Suppliers
- Tel
- 18951933883
- Fax
- QQ:1665798899
- leo.feng@liftpharm.com
- Country
- China
- ProdList
- 297
- Advantage
- 58
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2923
- Advantage
- 55
- Tel
- 021-50460086-9 15921403865
- Fax
- +86-21-50462321
- han_yajun@dctc.daicel.com
- Country
- China
- ProdList
- 6854
- Advantage
- 65
- Tel
- 021-53292253
- Fax
- 021-53292253
- biz@synches.com
- Country
- China
- ProdList
- 200
- Advantage
- 64
- Tel
- 021-68187180-819 13681683526
- Fax
- 021-68187179
- lchen@syncozymes.com
- Country
- China
- ProdList
- 186
- Advantage
- 55
- Tel
- 15928766785 15928766785
- Fax
- QQ961458712
- wupengcheng@astatech.cn
- Country
- China
- ProdList
- 1999
- Advantage
- 55
- Tel
- 86-21-37788339
- Fax
- 86-21-5768-0031
- Country
- China
- ProdList
- 76
- Advantage
- 55
- Tel
- 0523-18601685-898 18652728585
- sales@allyrise.com
- Country
- China
- ProdList
- 2741
- Advantage
- 60
- Tel
- 021-60345187 13671753212
- Fax
- 021-34702061
- lzz841106@aliyun.com
- Country
- China
- ProdList
- 10287
- Advantage
- 55
- Tel
- 18905173768
- Fax
- 025-83263139
- sales@dolonchem.com
- Country
- China
- ProdList
- 2297
- Advantage
- 50
- Tel
- 025-58849295 18951903616;
- Fax
- 025-68650336
- info@adooq.cn
- Country
- China
- ProdList
- 2989
- Advantage
- 60
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4153
- Advantage
- 55
- Tel
- 18101936766
- Fax
- 021-58583907
- eileen@shmychem.com
- Country
- China
- ProdList
- 351
- Advantage
- 55
- Tel
- +86 (21) 61919736
- Fax
- +86 (21) 61919739
- Country
- China
- ProdList
- 241
- Advantage
- 55
- Tel
- 28-87999436 02887999436
- Fax
- QQ:2746983436
- sales@sano-chem.com
- Country
- China
- ProdList
- 3929
- Advantage
- 55
- Tel
- 010-80828512 18001163873
- Country
- China
- ProdList
- 58
- Advantage
- 55
- Tel
- 0576-89085261 15867635987
- Fax
- 0576-89085262
- jasonhu09@163.com
- Country
- China
- ProdList
- 442
- Advantage
- 50
- Tel
- 021-38751876 15000076078
- Fax
- 021-50275764
- Info@rochipharma.com
- Country
- China
- ProdList
- 561
- Advantage
- 55
- Tel
- +86-400-851-9921
- Fax
- +86-10-82826195
- sales@pharmacodia.com
- Country
- China
- ProdList
- 2317
- Advantage
- 55
- Tel
- 020-61288194 61288195
- Fax
- 020-61288700
- 505721671@qq.com
- Country
- China
- ProdList
- 3868
- Advantage
- 58
- Tel
- 02781293128
- orders@biochemsafebuy.com
- Country
- China
- ProdList
- 9934
- Advantage
- 55
- Tel
- 021-021-20242659 18930833303
- Fax
- +86 (21) 2024-2659
- order@changyanchem.com
- Country
- China
- ProdList
- 5008
- Advantage
- 55
- Tel
- 025-83453382-8005
- Fax
- 025-83453382
- sale@parabiochem.com
- Country
- China
- ProdList
- 9604
- Advantage
- 55
- Tel
- 0317-5296180 15533709196
- Fax
- 0317-5106596
- sale@enkepharma.com
- Country
- China
- ProdList
- 1647
- Advantage
- 55
- Tel
- 17754423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8011
- Advantage
- 62
- Tel
- 21-31433387 15618786686
- Fax
- QQ:1369748377
- sales@rechemscience.com
- Country
- China
- ProdList
- 2990
- Advantage
- 58
- Tel
- Fax
- -
- 13006575422@163.com
- Country
- China
- ProdList
- 6357
- Advantage
- 58
- Tel
- 027-83991130 18627774460
- Fax
- 027-83991130
- 1718093273@QQ.COM
- Country
- China
- ProdList
- 1891
- Advantage
- 58
- Tel
- 571-89925085
- Fax
- 0086-571-89925065
- sales@amadischem.com
- Country
- China
- ProdList
- 131981
- Advantage
- 58
- Tel
- 027-59402396 13419635609
- Fax
- 027-83989310
- 13419635609@163.com
- Country
- China
- ProdList
- 1992
- Advantage
- 55
- Tel
- 0550-5196001 15000891977
- Fax
- 0550-5196001
- wj520wjxby@126.com
- Country
- China
- ProdList
- 1836
- Advantage
- 55
- Tel
- 0512-68131995 13862051930
- Fax
- 0512-68131995
- Country
- China
- ProdList
- 361
- Advantage
- 55
- Tel
- 86-(0)29-85992781 17792393971
- info@lynnchem.com
- Country
- China
- ProdList
- 4587
- Advantage
- 58
- Tel
- 010-88886666-01 13112345678
- Fax
- CDXH21@126.com
- loyson@tcypharm.com
- Country
- China
- ProdList
- 595
- Advantage
- 55
- Tel
- 027-027-83778875 15807197853
- Fax
- 027-83991220
- 15807197853@163.com
- Country
- China
- ProdList
- 3979
- Advantage
- 58
- Tel
- 021-58180488
- Fax
- 021-58180499
- sales@MedChemLeader.com
- Country
- China
- ProdList
- 999
- Advantage
- 58
- Tel
- +86 18721201413
- Fax
- +86 (21) 5775-8967
- sales@biopharmaleader.com
- Country
- China
- ProdList
- 1720
- Advantage
- 58
- Tel
- 571-85586718 +8613336195806
- Fax
- +86-571-85864795
- sales@capotchem.com
- Country
- China
- ProdList
- 29797
- Advantage
- 60
- Tel
- 010-57862036 18811083386
- msales@mesochem.com
- Country
- China
- ProdList
- 190
- Advantage
- 58
- Tel
- 027-87466105 15377573527
- 2678564200@qq.com
- Country
- China
- ProdList
- 17997
- Advantage
- 58
- Tel
- 021-60345187 13917602471
- Fax
- 021-60345187
- lzz841106@aliyun.com
- Country
- China
- ProdList
- 9908
- Advantage
- 58
- Tel
- 027-50476178
- Fax
- QQ644526144
- 644526144@qq.com
- Country
- China
- ProdList
- 418
- Advantage
- 58
- Tel
- 0371-67991738 13783628208
- Fax
- QQ 412703949
- carl@alchemist-pharm.com
- Country
- China
- ProdList
- 1877
- Advantage
- 58
- Tel
- 027-51831887 15337167856
- Fax
- 027-51837635 QQ1165326703
- hubeixinyuanshun@163.com
- Country
- China
- ProdList
- 10305
- Advantage
- 58
- Tel
- 13206083609
- 443187936@qq.com
- Country
- China
- ProdList
- 86
- Advantage
- 58
- Tel
- 0371-0371-63315541 13323832564
- Fax
- QQ:3001332135
- 3001332135@qq.com
- Country
- China
- ProdList
- 9998
- Advantage
- 58
- Tel
- 025-58786926 18951781718
- Fax
- 025-58786926
- zbbgz2009@163.com
- Country
- China
- ProdList
- 311
- Advantage
- 58
- Tel
- 025-84767922 18936879710
- sales@abydoscientific.com
- Country
- China
- ProdList
- 1029
- Advantage
- 58
- Tel
- 027-50478167
- Fax
- QQ 252994272
- 252994272@qq.com
- Country
- China
- ProdList
- 277
- Advantage
- 58
- Tel
- 010-82387566 18001021521;
- Fax
- 82387566-801
- sales@mreda.com.cn
- Country
- China
- ProdList
- 21450
- Advantage
- 58
View Lastest Price from Eluxadoline manufacturers
- Product
- Eluxadoline 864821-90-9
- Price
- US $0.00-0.00/KG
- Min. Order
- 1g
- Purity
- 99%
- Supply Ability
- 50kg/month
- Release date
- 2019-08-16
- Product
- Eluxadoline 864821-90-9
- Price
- US $2.00/kg
- Min. Order
- 1kg
- Purity
- 98%
- Supply Ability
- Ask
- Release date
- 2018-12-19